Synopsis:

The presentation will address the rationale for antibody therapy for Non-Hodgkin's B Cell Lymphoma and the rationale for selecting CD20 as a target antigen.

The debate around non-selective B cell depletion and risks of infections, patent issues and the need for better gene expression technology will be discussed. Manufacturing and process development capabilities and impact on partnering biopharmaceuticals, preclinical studies with FDA participation were also issues faced during development of Rituxan.

Clinical trials as drivers for product approval, market adoption and expansion and future trends with anti-CD20 antibodies and combination therapies will be described.

Presenter Bio:

Dr. Hanna is former Executive Vice President of Research at Biogen Idec. He assumed this responsibility after the merger of IDEC Pharmaceutical and Biogen in 2002.

From 1990 to 2002, Dr. Hanna served as VP of Research and then was promoted to Senior VP of Research and Pre-Clinical Development and then Chief Scientific Officer at IDEC Pharmaceuticals. During his tenure at IDEC, Dr. Hanna led a research team through the discovery and pre-clinical development of Rituximab and Zevalin, two antibodies now approved for therapy of non-Hodgkin’s B cell lymphoma.

From 1981 to 1990, Dr. Hanna served as a Director of the Department of Immunology at SmithKline Beecham focusing on autoimmune and chronic inflammatory diseases.

From 1978 to 1981, he was a research scientist at the NCI-Frederick Cancer Research Center, where he studied the role of natural host defenses against cancer metastasis.

From 1973 to 1978, Dr. Hanna was a lecturer in the Department of Immunology at Hebrew University Medical Center in Israel, where he received his Ph.D. in Immunology.

Meeting Information:

Space is Limited — Register Early to Guarantee Your Attendance!

Prior presentations:

Note: slides are displayed in a new window, left-click to advance, right-click to go back.

Speaker	PDF	Topic	Date
Dr. Richard Kim		Drug Transporters: In Vitro and Knockout Model Systems, Pharmacogenomics, and Clinical Relevance	April 19, 2011
Dr. Jerry Galluppi		Biotherapeutic Drug Research and Development: A Growing Role for the DMPK Scientist	October 5, 2010
Dr. Dennis Smith		Does drug metabolism hold its future in its own hands?	April 27, 2010
Dr. Paul F. Hollenberg		Mechanism-Based Inactivation of Human Cytochromes P450	October 6, 2009
Dr. Jack H. Dean Dr. Thomas Baillie		Challenges & Opportunities in Drug Development from a Drug Safety and Metabolism Perspective	May 19, 2009
Eric Johnson, Ph.D.		Characterization of Substrate/Inhibitor Binding to Drug-Metabolizing Cytochrome P450 Monooxygenases using X-ray Crystallography	September 30, 2008
Dr. Kenneth E. Thummel, Ph.D.		Regulation Of Intestinal CYP3A By VDR: Implications And Safety Of Oral Therapeutics	May 7, 2008
Dr. Anthony Lu, Ph.D.		Why Is The Liver Microsomal Cytochrome P450 Such A Versatile And Unique Enzyme?	September 12, 2007
Dr. Scott Obach, Ph.D.		Leveraging ADME Data In Metabolites In Safety Testing (MIST)	April 18, 2007
Dr. Sidney Nelson, Ph.D.		Drug Metabolism and Chemical Structural Alerts	September 27, 2006
Richard B. Kim, MD		Relevance and Utility of Transporters to Drug Discovery and Development	September 21, 2005
Dr. Frederick P. Guengerich, Ph.D.		Human Cytochrome P450 2A6 as a Case History:  Flavors, Smoke, Blue Roses, New Drugs & Basics of a P450	April 27, 2005
Dr. Leslie Benet, Ph.D.		Predicting Drug Disposition via Application of BCS: Transport/Absorption/Elimination Interplay and BDDCS	September 29, 2004
Dr. Christopher A. Lipinski, Ph.D.		ADME/Tox: How Low Can You Go And How Do You Recover?	April 21, 2004

A Special Thank You to our April 2012 meeting Sponsors!

Gold Sponsor

Triangle Research Labs

Silver Sponsors

Celsis In Vitro Technologies

Absorption Systems

Bronze Sponsors

Tandem Labs, a LabCorp Company

For more information on sponsoring SCDMDG, please refer to our sponsorship guidelines.